VRTX Financial Facts
Restructuring expense: -419KRoyalty revenues: 8.54M
See Full Income Statement
Total liabilities: 1.36B
Accrued interest: 6.7M
See Full Balance Sheet
Vertex Pharmaceuticals Incorporated (VRTX) Earnings
|
Expand Research on VRTX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +13.9% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +2.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7/27/22 | Q222 | N/A | $3.54 | N/A | N/A | $2.13B | N/A | N/A | N/A | ||
| 5/5/22 |  |
Q122 | $3.52 | $3.48 | +$0.04 | $2.1B | $2.07B | N/A |  | | Details |
| 1/26/22 | |
Q421 | $3.37 | $3.29 | +$0.08 | $2.07B | $2B | N/A | | | Details |
| 11/2/21 | |
Q321 | $3.56 | $3.08 | +$0.48 | $1.98B | $1.86B | N/A | | | Details |
| 7/29/21 | |
Q221 | $3.11 | $2.28 | +$0.83 | $1.79B | $1.72B | N/A | | | Details |
| 4/29/21 | |
Q121 | $2.98 | $2.69 | +$0.29 | $1.72B | $1.66B | N/A | | | Details |
| 2/1/21 | |
Q420 | $2.51 | $2.59 | -$0.08 | $1.63B | $1.58B | N/A | | | Details |
| 10/29/20 | |
Q320 | $2.64 | $2.34 | +$0.30 | $1.54B | $1.48B | N/A | | | Details |
